GL1X · GenesisL1 explorer

MolNFT v1 · #156722 · protein

Non-receptor protein tyrosine phosphatase SHP2 in complex with allosteric inhibitor pyrazolo-pyrimidinone 5

6MDB · Tyrosine-protein phosphatase non-receptor type 11: “Non-receptor protein tyrosine phosphatase SHP2 in complex with allosteric inhibitor pyrazolo-pyrimidinone 5”. X-ray diffraction, 2 ligands (JE4, PO4), 13 pockets (best druggability…

PDB
6MDB
Type
protein
Length
968 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein phosphatase non-receptor type 11
EC
3.1.3.48
UniProt
Q06124
Ligands
JE4, PO4
Pockets
13 · best druggability 0.69

Structure

x-ray diffraction · 2 distinct chains · 29% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48)protein48729% helix, 27% strandQ06124
BTyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48)protein48130% helix, 26% strandQ06124

Ligands and binding sites

  • JE4 · 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)-5-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · 3 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

13 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18530.690.7558empty
23300.660.8128JE4
34200.650.7835JE4
41180.500.8120empty
51120.480.8016empty

Interfaces

1 interface between chains.

  • A–B · 170 Ų buried · 1 hydrogen bond · protein-protein

Compared structures

  • 6MDB · Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.